A role for cathepsin Z in neuroinflammation provides mechanistic support for an epigenetic risk factor in multiple

Euan R O Allan1, Rhiannon I Campden1,2, Benjamin W Ewanchuk1,2

  • 1Snyder Institute for Chronic Disease, University of Calgary, Calgary, AB, T2N 4 N1, Canada.

Abstract

Insights

Cathepsin Z deficiency reduces neuroinflammation in multiple sclerosis models by lowering IL-1β. This highlights cathepsin Z

Area of Science:

  • Neuroimmunology
  • Epigenetics
  • Inflammation

Background:

  • Hypomethylation of the cathepsin Z locus is a potential epigenetic risk factor for multiple sclerosis (MS).
  • Cathepsin Z, a lysosomal cysteine cathepsin, is primarily expressed by antigen-presenting cells and linked to neuroinflammatory disorders.
  • Its specific role in mediating neuroinflammation remained unestablished.

Purpose of the Study:

  • To investigate the role of cathepsin Z in neuroinflammation and experimental autoimmune encephalomyelitis (EAE), a model for MS.
  • To determine the impact of cathepsin Z deficiency on antigen presentation and cytokine production.
  • To elucidate the effect of cathepsin Z deficiency on T cell responses in the context of neuroinflammation.

Main Methods:

  • Experimental autoimmune encephalomyelitis (EAE) was induced in wildtype and cathepsin Z-deficient mice.
  • In vitro analysis of autoantigen processing, presentation, and cytokine (IL-1β, IL-18) production by antigen-presenting cells.
  • In vivo assessment of CD4+ T cell activation, migration, and central nervous system (CNS) infiltration.

Main Results:

  • Mice deficient in cathepsin Z exhibited reduced neuroinflammation and significantly lower circulating IL-1β levels during EAE.
  • Cathepsin Z deficiency did not affect myelin oligodendrocyte glycoprotein (MOG) processing, presentation, or MOG-specific CD4+ T cell activation and trafficking.
  • Antigen-presenting cells lacking cathepsin Z showed reduced IL-1β secretion, impairing Th17 responses crucial for EAE and MS pathogenesis.

Conclusions:

  • Cathepsin Z plays a novel role in promoting IL-1β-driven neuroinflammation.
  • Targeting cathepsin Z may offer a therapeutic strategy for MS by modulating IL-1β production and Th17 responses.